Media ReleasesEco Quest

View All Eco Quest News

EcoQuest, Cynata Therapeutics - CEO Presentation: Becoming a Next Generation Stem Cell Company

Stem Cell Field is Emerging

Analogous to monoclonal antibody enabling technologies in ‘80s and ‘90s which now have a therapeutic market value in excess of US$44.6b;

Commercial stem cell products are entering the market:
-  Prochymal (GvHD) – Osiris (USA)
-  Cartistem (Osteoarthritis) – Medipost/Dong-A (Korea);

Most stem cell companies attractively priced based on forward estimates;

Multiple products in Phase 2 and 3
-  Sector news flow
-  Creates opportunities for Cynata;

Big pharma partnering/M&A:
-  Teva/Mesoblast
-  Pfizer/Athersys
-  United Therapeutics/Pluristem
-  Novartis/Regenerex.

To view Presentation please download PDF below:

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.